These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Deciphering the role of VPS35 in Parkinson's disease. Williams ET; Moore DJ J Neurosci Res; 2018 Aug; 96(8):1339-1340. PubMed ID: 29775219 [No Abstract] [Full Text] [Related]
29. A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson's disease model. Wang W; Ma X; Zhou L; Liu J; Zhu X Hum Mol Genet; 2017 Feb; 26(4):781-789. PubMed ID: 28040727 [TBL] [Abstract][Full Text] [Related]
30. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant. Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683 [TBL] [Abstract][Full Text] [Related]
31. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1. Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146 [TBL] [Abstract][Full Text] [Related]
34. Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity. Bi F; Li F; Huang C; Zhou H Int J Biol Sci; 2013; 9(2):149-55. PubMed ID: 23411763 [TBL] [Abstract][Full Text] [Related]
35. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N. Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282 [TBL] [Abstract][Full Text] [Related]
36. Increased copper toxicity in Saccharomyces cerevisiae lacking VPS35, a component of the retromer and monogenic Parkinson disease gene in humans. Sowada N; Stiller B; Kubisch C Biochem Biophys Res Commun; 2016 Aug; 476(4):528-533. PubMed ID: 27262440 [TBL] [Abstract][Full Text] [Related]
37. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress. McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383 [TBL] [Abstract][Full Text] [Related]
38. Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases. Follett J; Bugarcic A; Collins BM; Teasdale RD Curr Protein Pept Sci; 2017; 18(7):687-701. PubMed ID: 26965691 [TBL] [Abstract][Full Text] [Related]
39. Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation. Follett J; Bugarcic A; Yang Z; Ariotti N; Norwood SJ; Collins BM; Parton RG; Teasdale RD J Biol Chem; 2016 Aug; 291(35):18283-98. PubMed ID: 27385586 [TBL] [Abstract][Full Text] [Related]
40. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]